Related Experiment Video

Updated: Jul 1, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Neonatal intraventricular haemorrhage associated with maternal use of paroxetine

Yvonne C M Duijvestijn1, Mathijs D Kalmeijer, Anneke L M Passier

  • 1Department of Pediatrics, Emma Children's Hospital/Academic Medical Centre, Amsterdam, The Netherlands.

British Journal of Clinical Pharmacology
|December 4, 2003
PubMed

Insights

Selective serotonin reuptake inhibitors (SSRIs) can reduce platelet function. This case highlights a potential link between maternal paroxetine use and intraventricular hemorrhage in newborns.

Area of Science:

  • Neonatal neurology
  • Pharmacology
  • Hematology

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressants.
  • SSRIs are known to affect platelet serotonin uptake and function.
  • Paroxetine is an SSRI that crosses the placenta during pregnancy.

Observation:

  • A 6-hour-old infant presented with a large intraventricular hemorrhage.
  • The infant's mother reported using paroxetine throughout her pregnancy.
  • No other risk factors for intraventricular hemorrhage were identified.

Findings:

  • The case suggests a potential association between maternal paroxetine use and neonatal intraventricular hemorrhage.
  • Reduced platelet function due to SSRI exposure may contribute to bleeding events.
  • Further research is needed to confirm this association and elucidate the mechanism.

Implications:

  • This finding warrants consideration of SSRI use during pregnancy, particularly paroxetine.
  • Neonatal care providers should be aware of this potential risk.
  • This case underscores the importance of evaluating medication effects on fetal and neonatal outcomes.

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...